CYNO (US2325772059)
Cynosure Inc. develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health. The Company operates through aesthetic treatment products and services segment. It markets radiofrequency (RF) energy sourced medical devices for precision surgical applications, such as facial plastic and general surgery; gynecology; ear, nose and throat procedures; ophthalmology; oral and maxillofacial surgery; podiatry, and proctology.
Market: Nasdaq
Average yearly return: 28%
Yield: N/A
Marketperformer
Cynosure Inc. develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health. The Company operates through aesthetic treatment products and services segment. It markets radiofrequency (RF) energy sourced medical devices for precision surgical applications, such as facial plastic and general surgery; gynecology; ear, nose and throat procedures; ophthalmology; oral and maxillofacial surgery; podiatry, and proctology.
Market: Nasdaq
Fair value: $ 54.50
Discount: 5%Average yearly return: 28%
Yield: N/A
Marketperformer
According to the latest SEC Filings, institutions owning shares of Cynosure, Inc. (NASDAQ:CYNO) of the Healthcare sector have increased their positions by 1.54% over the past 3 months. Institutions now own 98.10% of the company.
No comments:
Post a Comment